糖尿病肾病的生物治疗及研究进展

Advances in biotherapy of diabetic nephropathy

糖尿病肾病(diabetic nephropathy,DN)是终末期肾脏病的主要病因之一,且与心血管发病率、病死率升高密切相关。目前DN的治疗方法主要包括严格控制血糖、降低血压、使用肾素-血管紧张素-醛固酮系统阻断剂减少尿蛋白。然而这些只是对症治疗,目前还未发现专门针对DN的有效治疗方法。本文阐述了一些与DN发病机制相关的生物分子如胰高血糖素样肽-1(GLP-1)、整合素αVβ3、内皮素A(ETA)、趋化因子受体2(CCR2)等,并探讨了这些分子在DN发病机制中的作用及其临床研究进展。

Diabetic nephropathy(DN),one of the causes of end-stage renal disease,is closely related to increased incidence of cardiovascular morbidity and mortality.Current treatment approaches of DN include strict control of blood glucose,lowering blood pressure and reducing albuminuria by renal-angiotensin-aldosterone system blockers.However,these are only symptomatic treatment,and effective treatment of DN is still not available.This review explores the role and clinical research advances of some biomolecules in the pathogenesis of DN,such as glucagon-like peptide-1(GLP-1),integrinαVβ3,endothelin A(ETA),chemokine receptor2(CCR2),etc.